Hexarelin

GHS-R1a Agonism: The Primary GH Pulse#

Hexarelin is a synthetic hexapeptide that binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor targeted by endogenous ghrelin — on pituitary somatotrophs and hypothalamic neurons. Activation triggers a phospholipase-C / IP₃ / calcium cascade that directly depolarizes somatotrophs, forcing a sharp, pulsatile release of stored GH. The pulse is clean and physiological in shape (unlike the flat curve of exogenous rHGH), but supra-physiological in amplitude — several-fold larger than a natural GH pulse and larger than what GHRP-6 or GHRP-2 produce at equimolar doses.

"Hexarelin induced a dose-dependent GH response, with maximal stimulation at 2 micrograms/kg, producing significantly higher GH peaks than GHRP-6 at equimolar doses." — Imbimbo BP, Smith RG, Thorner MO, et al. J Clin Endocrinol Metab, 1994

Practical consequence: a 100 mcg SC shot produces a GH spike starting at ~15–30 minutes, peaking near 30–60 minutes, and returning to baseline by ~2 hours. That window is when lipolysis, IGF-1 synthesis signalling, and recovery benefits are happening — which is why timing (fasted AM, pre-workout, pre-bed) matters more here than with slow-release compounds.

Dual-Pathway Synergy with GHRH#

GHS-R1a agonism doesn't just trigger GH release directly — it also suppresses hypothalamic somatostatin (the brake on GH) and amplifies GHRH tone. This is why hexarelin stacks so cleanly with a GHRH analog like CJC-1295 / Mod GRF 1-29: the two peptides hit the somatotroph through independent receptor systems, and the combined pulse is roughly the sum of each alone — sometimes more. Hexarelin removes the somatostatin brake while CJC-1295 presses the GHRH accelerator.

The catch: hexarelin uniquely blunts the subsequent GHRH response after chronic dosing, a feature not shared by ipamorelin or GHRP-2. This is one of the mechanistic reasons hexarelin cycles are capped short — you're not just desensitizing GHS-R1a, you're partially degrading the GHRH arm too.

Downstream IGF-1 and Recomp Signaling#

Each GH pulse drives hepatic IGF-1 production, which is where most of the muscle-preserving, collagen-synthesis, and recomp effects actually live. Expect a 30–60% IGF-1 bump above baseline in the first 2–3 weeks of a well-run protocol, trending back toward baseline as desensitization sets in by weeks 4–6. The GH pulse itself drives acute lipolysis (free fatty acid release from adipocytes within 30–60 min) and nitrogen retention — modest in magnitude per pulse, but cumulative across a cycle when dosed 2–3× daily.

"Hexarelin is the most effective synthetic GHRP tested so far, with a greater GH-releasing activity than GHRP-6 in humans. Chronic administration induces desensitization limiting long-term efficacy." — Ghigo E, Arvat E, Muccioli G, Camanni F. Eur J Endocrinol, 1997

This is the honest ceiling on hexarelin vs. rHGH: you get a handful of potent physiological pulses per day, not the 24/7 elevation of exogenous GH. Good for recomp, recovery, and connective tissue; not a mass-builder on the level of rHGH + insulin + AAS stacks.

CD36 Binding: The Cardiovascular Side-Channel#

Hexarelin has a second, GH-independent mechanism that sets it apart from other GHRPs: direct binding to CD36, a scavenger receptor on cardiomyocytes, macrophages, and vascular endothelium. CD36 engagement activates PPARγ, reduces oxidized-LDL uptake in macrophages (anti-atherogenic), and is the mechanistic basis for the cardioprotective effects seen in rodent ischemia/reperfusion models.

"Hexarelin directly interacts with the CD36 receptor and increases PPARγ activity, suggesting potential benefits for cardiovascular function independent of GH release." — Rodrigue-Way A, Demers A, Ong H, Tremblay A. PPAR Research, 2008

"Pretreatment with hexarelin significantly reduced infarct size and cardiomyocyte apoptosis after I/R injury, supporting its cardioprotective effect in vivo." — Mao Y, Tokudome T, Kishimoto I, et al. PLOS ONE, 2017

Honest caveat: the cardioprotective data is rodent-level. It's a reasonable talking point for users running heavy AAS who want a peptide with favorable off-target effects, but don't treat it as a substitute for actually managing lipids, blood pressure, and hematocrit.

The Cortisol and Prolactin Tax#

The limitation of hexarelin — and the reason ipamorelin often wins for long-term users — is ACTH co-release. GHS-R1a activation at this potency also triggers corticotroph activation, roughly doubling cortisol and prolactin acutely after a single dose. At 100 mcg per shot this is manageable; pushing per-shot doses to 200–300 mcg stacks the cortisol/prolactin curve faster than it stacks the GH curve, which is why 100 mcg is the practical saturation dose. More peptide per injection buys you stress hormones, not GH.

For users stacking with 19-nor AAS (deca, tren) where prolactin is already a concern, keep cabergoline on hand or rotate to ipamorelin. For a short recomp or healing blast, the cortisol bump is transient enough to ride out.

Desensitization: Why Cycles Stay Short#

Chronic GHS-R1a agonism downregulates the receptor. Twice-daily dosing for 4+ weeks measurably attenuates the GH response, and continuous infusion attenuates it within days. This is baked into hexarelin's pharmacology, not a sourcing or dosing issue. The mitigation is structural: 4–8 week cycles, equal time off, and rotating to ipamorelin or a pure GHRH analog during the off-block to let GHS-R1a resensitize. Users who run hexarelin year-round report exactly what the receptor biology predicts — the first month works, months 2–4 don't.

Common (most users)#

• Head rush / flushing right after injection — transient, lasts a few minutes. Inject sitting down for the first few shots until you know how you respond.
• Tingling or numbness (hands, face) — classic GH-pulse sign, usually a good indicator the peptide is dosed correctly. No action needed; often fades within the first 1–2 weeks.
• Hunger spike 20–40 min post-injection — ghrelin-receptor agonism. Useful on a bulk, annoying on a cut. On a deficit, time the shot pre-workout or pre-bed rather than mid-day.
• Lethargy / mild drowsiness post-shot — dose pre-bed to turn this into a feature rather than a bug. AM users can shift the dose to pre-workout instead.
• Water retention / puffy hands and face in the first 2–3 weeks — standard GH side effect, settles as IGF-1 plateaus. Manage sodium and keep potassium intake up; don't chase it with a diuretic.
• Vivid dreams / deeper sleep from the pre-bed dose — generally welcomed. If it tips into insomnia, move the shot earlier in the evening.
• Injection-site irritation — rotate sites on the abdominal fat pad; swirl (don't shake) reconstituted peptide; keep vials cold.

Uncommon (dose-dependent or individual)#

• Cortisol elevation — hexarelin's biggest knock versus ipamorelin. Single doses roughly double acute cortisol via ACTH co-release. At 100 mcg per shot this is tolerable; at 200–300 mcg per shot you're buying cortisol, not more GH. Stay at the 100 mcg saturation dose — the GH curve plateaus there.

"Hexarelin is the most effective synthetic GHRP tested so far, with a greater GH-releasing activity than GHRP-6 in humans. Chronic administration induces desensitization limiting long-term efficacy." — Ghigo et al., Eur J Endocrinol (1997)

• Prolactin elevation — matters if you're stacking with 19-nors (deca, tren) where prolactin is already a problem. Keep cabergoline on hand (0.25 mg twice weekly is typical) and check prolactin at week 4 if symptomatic (nipple sensitivity, libido drop, ED).
• Mild insulin resistance / fasted glucose creep — the GH pulse antagonizes insulin acutely. Clinically irrelevant at community doses in a healthy user; check fasted glucose and HbA1c at week 4 if running the full 8 weeks or stacking with rhGH-adjacent compounds. Back off if fasted glucose trends >100 mg/dL.
• Carpal-tunnel-style wrist/hand pain — GH-mediated soft-tissue swelling. Drop to 100 mcg once daily or cut the cycle short; resolves within days of stopping.
• Appetite overshoot on a cut — if hunger is breaking your deficit, this is the wrong GHRP for you. Rotate to ipamorelin, which is appetite-neutral.
• IGF-1 tachyphylaxis by week 4–6 — IGF-1 typically bumps 30–60% early, then drifts back as GHS-R desensitizes. This isn't a "side effect" so much as the reason cycles cap at 6–8 weeks.

Rare but serious#

• Persistent hypertension or edema — if BP climbs and stays climbed, or ankles are pitting, stop and reassess. GH-driven sodium retention should be mild and transient at these doses; anything more warrants a workup.
• New-onset or worsening diabetic retinopathy in users with pre-existing diabetes — GH/IGF-1 axis stimulation is contraindicated in this population. Stop immediately on any visual change.
• Accelerated growth of an undiagnosed malignancy — theoretical but biologically plausible given GH/IGF-1's mitogenic profile. Anyone with a personal or strong family history of hormone-sensitive cancers should not run GH secretagogues.
• Severe prolactin symptoms (galactorrhea, sustained ED, mood crash) — rare on hexarelin monotherapy, more likely when stacked with nandrolone or trenbolone. Stop, pull bloods, add caber.

Hard contraindications#

• Active malignancy — do not run GH secretagogues with any active or recently treated cancer. The GH/IGF-1 axis is mitogenic.
• Diabetic retinopathy or uncontrolled diabetes — GH elevation can accelerate proliferative retinopathy.
• Pregnancy or lactation — no data, do not use.
• Concurrent exogenous rhGH — pointless and counterproductive. Exogenous GH feedback-suppresses the somatotrophs that hexarelin is trying to pulse; you get the cost without the benefit. Pick one.
• History of pituitary adenoma or active Cushing's — do not stimulate an already-pathologic axis.

Gender considerations and PCT#

Hexarelin is non-hormonal with respect to sex steroids — same 100 mcg saturation dose for men and women, no virilization concern, no HPTA suppression, no PCT required. The cortisol and prolactin bumps apply equally to both sexes. Women on a hair-retention or aesthetics stack can run hexarelin without worrying about the sex-steroid axis. Cycle discipline (4–8 weeks on, equal time off, or rotate to ipamorelin during the off-block) matters more than any gender-specific consideration — desensitization is the real ceiling on this compound, not toxicity.